Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

855
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
855
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

909
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
909
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

789
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
789
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

803
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

707
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
707
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.5K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Explantation of durable ventricular assist device for myocardial functional recovery in children: A report from the ACTION registry.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Prospective Multicenter Evaluation of a Novel Active Driving System for Pediatric Ventricular Assist Device Support.

Journal of the American College of Cardiology·2026
Same author

Multicenter Registry Analysis of Bivalirudin for Primary Anticoagulation in Pediatric HeartMate 3 Recipients: ACTION Analysis.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Capturing Physiological Data in Children With Heart Failure Using Wearable Digital Technology: Lessons From Pilot Project.

CJC pediatric and congenital heart disease·2026
Same author

Heart Transplantation and Ventricular Assist Device in Duchenne Muscular Dystrophy: A New Era.

Pediatric transplantation·2025
Same author

Authors Insights on the Updated International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014).

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 15, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

20.4K

左心室非収縮性心筋病変症 左心室非収縮性心筋病変症

Jeffrey A Towbin1, Angela Lorts1, John Lynn Jefferies1

  • 1The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Lancet (London, England)
|April 14, 2015
PubMed
まとめ
この要約は機械生成です。

左心室非収縮症 (LVNC) は,心筋の異常な発達による珍しい心筋病です. 遺伝的要因と経路の障害は,心不全,心律乱れ,突然死などのリスクに寄与します.

さらに関連する動画

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K

関連する実験動画

Last Updated: Apr 15, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

20.4K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K

科学分野:

  • 心臓病学 心臓病学
  • 遺伝学 遺伝学とは
  • 分子生物学は分子生物学である.

背景:

  • 左心室非収縮症 (LVNC) は,最近分類された心筋病です.
  • 異常な左心房トラベキュレーションが特徴であり,しばしば心機能不全や先天性心疾患と関連しています.
  • 患者は心不全,不律,突然死などのリスクに直面し,遺伝的要因は症例の30〜50%に関与しています.

研究 の 目的:

  • 左心室非収縮 (LVNC) の現在の理解を要約します.
  • LVNCの遺伝的基礎,病理生理学,および臨床的症状を強調する.
  • LVNC患者に対する現在および必要な治療戦略を見直す.

主な方法:

  • 左心室非収縮 (LVNC) に関する研究の文献レビュー.
  • サルコメリックおよび細胞骨格タンパク質を含む遺伝的関連性の分析.
  • LVNCの病原性におけるNOTCHシグナル伝達経路とミトコンドリア機能障害の検討.

主要な成果:

  • LVNCは心房の異常な発達を伴い,様々な心疾患を引き起こす.
  • 収縮性または細胞骨格タンパク質の遺伝子変異は,一般的な原因です.
  • NOTCHシグナル伝達とミトコンドリア機能障害の障害は,特に先天性心疾患において重要な役割を果たします.

結論:

  • LVNCは,無症状から重度の心不全まで,さまざまな臨床結果を示します.
  • 管理は,心臓機能の改善,心律不全の管理,突然の死の予防に焦点を当てています.
  • LVNC患者の理解と結果を改善するためにさらなる研究が必要です.